» Articles » PMID: 31016619

MiR-144-3p: a Novel Tumor Suppressor Targeting MAPK6 in Cervical Cancer

Overview
Specialties Biochemistry
Physiology
Date 2019 Apr 25
PMID 31016619
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer is the third most common gynecologic cancer in the world. Exploration of the molecular mechanism underlying cervical cancer pathogenesis will provide new insights into the development of novel therapies. In this study, we were aimed to characterize a novel miRNA in cervical cancer tumorigenesis. First, we measured the expressional change of miR-144-3p in clinical tissues and cancer cells. Second, we employed cell proliferation, cell migration, and invasion assays to understand its functional role in cervical cancer. Then, we confirmed in vitro findings in xenograft cancer model. Last, we mapped out a downstream target of miR-144-3p and validated its functional role in cancer cells. In the results, miR-144-3p was found significantly downregulated in cervical cancer cells and tissues. Over-expressing miR-144-3p suppressed cancer cells growth and metastasis. Consistent with in vitro results, over-expressing miR-144-3p led to tumor growth inhibition in vivo. Further on, MAPK6 was identified as an endogenous target of miR-144-3p in cervical cancer. Knocking down MAPK6 inhibited cervical cancer cells proliferation, migration, and invasion potential. Our investigation was the first time to report miR-144-3p as a tumor suppressive miRNA in cervical cancer. It inhibited tumor growth by targeting MAKP6. The newly identified signalling axis may serve as novel therapeutic targets to manage cervical cancer.

Citing Articles

Anticancer Effects of MAPK6 siRNA-Loaded PLGA Nanoparticles in the Treatment of Breast Cancer.

Toruntay C, Poyraz F, Susgun S, Yucesan E, Mansuroglu B J Cell Mol Med. 2025; 29(2):e70309.

PMID: 39823246 PMC: 11740982. DOI: 10.1111/jcmm.70309.


Dr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.

Rahman M, Ghorai S, Panda K, Santiago M, Aggarwal S, Wang T Noncoding RNA Res. 2024; 11:22-37.

PMID: 39736851 PMC: 11683234. DOI: 10.1016/j.ncrna.2024.11.001.


ERK3 is involved in regulating cardiac fibroblast function.

Sahadevan P, Dingar D, Nawaito S, Nair R, Trepanier J, Sahmi F Physiol Rep. 2024; 12(11):e16108.

PMID: 38872461 PMC: 11176743. DOI: 10.14814/phy2.16108.


Novel circular RNA circ-0002727 regulates miR-144-3p/KIF14 pathway to promote lung adenocarcinoma progression.

Li Y, Hong X, Zhai J, Liu Y, Li R, Wang X Front Cell Dev Biol. 2023; 11:1249174.

PMID: 38033864 PMC: 10686231. DOI: 10.3389/fcell.2023.1249174.


MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis.

Rezaee A, Ahmadpour S, Jafari A, Aghili S, Tamehri Zadeh S, Rajabi A Front Oncol. 2023; 13:1215194.

PMID: 37854681 PMC: 10580988. DOI: 10.3389/fonc.2023.1215194.


References
1.
Banno K, Iida M, Yanokura M, Kisu I, Iwata T, Tominaga E . MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. ScientificWorldJournal. 2014; 2014:178075. PMC: 3910129. DOI: 10.1155/2014/178075. View

2.
Boulton T, Nye S, Robbins D, Ip N, Radziejewska E, Morgenbesser S . ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991; 65(4):663-75. DOI: 10.1016/0092-8674(91)90098-j. View

3.
Burd E . Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 16(1):1-17. PMC: 145302. DOI: 10.1128/CMR.16.1.1-17.2003. View

4.
Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E . Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer. 2005; 4:38. PMC: 1291396. DOI: 10.1186/1476-4598-4-38. View

5.
Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L . MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget. 2015; 6(28):25266-80. PMC: 4694830. DOI: 10.18632/oncotarget.4457. View